KRAS and rectal cancer: In human rectal cancer (RC), using a targeted sequencing approach, it was noticed that about 42% of RC has a co-occurrence of KRAS and TP53 mutation, while 32% of RC has a co-occurrence of KRAS and APC mutations [123].